Primo Brands Announces Date for Second Quarter 2025 Earnings Release and Conference Call
Primo Brands will host a conference call, to be simultaneously webcast, on Thursday, August 7, 2025 at 10:00 a.m. ET. A question-and-answer session will follow management's presentation. To participate, please call the following numbers:
Details for the Earnings Conference Call:
Date: August 7, 2025Time: 10:00 a.m. ETNorth America Dial-in: (888) 510-2154International Dial-in: (437) 900-0527Conference ID: 91812Webcast Link: https://app.webinar.net/4DVw0w9aWjk
Webcast for Second Quarter 2025 Earnings Conference Call:
A live audio webcast will be available through the Company's website at https://ir.primobrands.com. The webcast will be recorded and archived for playback on the investor relations section of the website following the event.
About Primo Brands Corporation
Primo Brands is a leading North American branded beverage company focused on healthy hydration, delivering responsibly sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every U.S. state and Canada.
Primo Brands has a comprehensive portfolio of highly recognizable and conveniently packaged branded water and beverages distributed across more than 200,000 retail outlets, including established 'billion-dollar brands' Poland Spring® and Pure Life®, premium brands like Saratoga® and Mountain Valley®, regional leaders such as Arrowhead®, Deer Park®, Ice Mountain®, Ozarka®, and Zephyrhills®, purified brands including Primo Water® and Sparkletts®, and flavored and enhanced brands like Splash Refresher™ and AC+ION®. These product offerings are sold directly across retail channels, including mass, food, convenience, natural, drug, wholesale, distributors, and home improvement, as well as food service accounts in North America.
Primo Brands also has extensive direct-to-consumer offerings with its industry-leading line-up of innovative water dispensers, which create consumer connectivity through recurring purchases across its Direct Delivery, Exchange and Refill offerings. Through Direct Delivery, Primo Brands delivers responsibly sourced hydration solutions direct to home and business customers. Through Exchange, consumers can visit approximately 26,500 retail locations and purchase a pre-filled, multi-use bottle of water that can be exchanged after use for a discount on the next purchase. Through its Refill offering, consumers have the option to refill empty multi-use bottles at approximately 23,500 self-service refill stations. Primo Brands also offers water filtration units for home and business customers across North America.
Primo Brands is a leader in reusable beverage packaging, helping to reduce waste through its multi-serve bottles and innovative brand packaging portfolio, which includes recycled plastic, aluminum, and glass. Primo Brands has a portfolio of over 90 springs and actively manages water resources to help assure a steady supply of quality, safe drinking water today and in the future. Primo Brands also helps conserve over 28,000 acres of land across the U.S. and Canada. Primo Brands is proud to partner with the International Bottled Water Association ('IBWA') in North America, which supports strict adherence to safety, quality, sanitation, and regulatory standards for the benefit of consumer protection. Primo Brands is committed to supporting the communities it serves, investing in local and national programs and delivering hydration solutions following natural disasters and other local community challenges.
Primo Brands employs more than 13,000 associates with dual headquarters in Tampa, Florida, and Stamford, Connecticut.
For more information, please visit www.primobrands.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia, July 2, 2025 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ('Neurizon' or 'the Company'), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: 'This license agreement with Elanco marks a watershed moment in Neurizon's journey to become a leader in the accelerated development of treatments for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is now well-positioned to accelerate the path to market and advance new treatment options for people affected by devastating neurodegenerative diseases.' Mr. Sergio Duchini, Non-Executive Chairman, commented: 'On behalf of the Board, I am pleased to endorse this landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also very happy to be making this important step in formalising our relationship with Elanco and look forward to building on this foundation as we progress towards finalising a supply agreement later this year.' Key Terms of the Licensing Agreement: Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco's data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement[2]. Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products, indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for milestone payments of up to US $65 million based on sales milestones[3]. Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products. Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply Agreement. Supply Agreement Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in H2 CY 2025. This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMP-compliant monepantel to support ongoing clinical development, regulatory submissions, and future global commercialisation of NUZ-001. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon® is a registered trademark of Neurizon Therapeutics Limited [1] NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications. [2] The amount is not material to Neurizon's current cash position [3] If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and commercial milestone payments will become due 30 days after the relevant milestone is met.
Malaysian Reserve
7 hours ago
- Malaysian Reserve
CRAFTSMAN®, Ace Hardware Foundation and Joe Gibbs Racing Team Up for Annual Racing for a Miracle Program
Racing for a Miracle supports Children's Miracle Network (CMN) Hospitals, including the Ann & Robert H. Lurie Children's Hospital in Chicago Ten children from the hospital will be honorary junior crew members for NASCAR driver Christopher Bell Junior crew members' art will be featured on Bell's No. 20 car in the July 6 race CRAFTSMAN will donate $100,000 to the Ace Hardware Foundation in support of CMN Hospitals Ace Hardware is celebrating CRAFTSMAN's continued support by offering customers 20% off** select CRAFTSMAN V20* Power Tools, Outdoor Power Equipment and Accessories CHICAGO, July 2, 2025 /PRNewswire/ — CRAFTSMAN®, a Stanley Black & Decker brand (NYSE: SWK), is proudly teaming up once again with the Ace Hardware Foundation and NASCAR driver Christopher Bell of Joe Gibbs Racing for the 19th Annual Racing for a Miracle program, which supports Children's Miracle Network Hospitals (CMN Hospitals). This year, CRAFTSMAN is donating $100,000 to the Ace Hardware Foundation for CMN Hospitals. Since 2006, Stanley Black & Decker and its brands have contributed more than $1.9 million to the Racing for a Miracle program. The program provides funding for vital treatments and healthcare services for children and their families at 170 CMN Hospitals across the U.S. and Canada. 'For nearly 20 years, we have seen firsthand the impact Racing for a Miracle, and our partnership with Ace Hardware Foundation and CMN Hospitals, has had for children and their families. We're always so inspired by their stories, and their strength and perseverance,' said Tony Merritt, Vice President of Sponsorships for Stanley Black & Decker. 'We're proud to be part of this legacy and happy to celebrate the incredible impact this program has made.' The donation to the Ace Hardware Foundation will take place during a tailgate at Ace Hardware corporate headquarters. At the tailgate, CRAFTSMAN, Ace Hardware and Christopher Bell will unveil the design for 2025 CRAFTSMAN Racing for a Miracle car with the help of ten children from the Ann & Robert H. Lurie Children's Hospital in Chicago. Ace Hardware Offers Special CRAFTSMAN® PromotionAdditionally, Ace Hardware is celebrating CRAFTSMAN's continued support of the Ace Hardware Foundation and the Racing for a Miracle program by offering customers 20% off** select CRAFTSMAN V20* Power Tools, Outdoor Power Equipment and Accessories. This offer is exclusive to Ace Hardware and is valid June 25th, 2025 through July 31, 2025 in-store and online. Visit or follow CRAFTSMAN® on Facebook and Instagram for updates on this year's Racing for a Miracle program. *Maximum initial battery voltage (measured without a workload) is 20 volts. Nominal voltage is 18 volts.**See store or for details and eligible products. Offer valid only on qualifying CRAFTSMAN products purchased 6/25/2025 through 7/31/2025, while supplies last. Offer valid at participating Ace Hardware stores, on and the Ace mobile app. May not be combined with any other discount or offer and does not apply to prior purchases. Discount does not apply to tax, shipping and handling, or assembly. If merchandise is returned, customer will receive discounted price paid. Other restrictions may apply. Void where prohibited. About CRAFTSMANCRAFTSMAN is the most trusted and recommended brand in Tools and Outdoor by DIYers.* With solutions for the home, yard and garage, CRAFTSMAN is committed to empowering DIYers at every stage of their journey. Crafted with the same innovation and expertise homeowners have come to expect and love, CRAFTSMAN is here to help DIYers BUILD ON™. For more information, visit or follow CRAFTSMAN on Facebook and Instagram. About Stanley Black & DeckerFounded in 1843 and headquartered in the USA, Stanley Black & Decker (NYSE: SWK) is a worldwide leader in Tools and Outdoor, operating manufacturing facilities globally. The Company's approximately 48,000 employees produce innovative end-user inspired power tools, hand tools, storage, digital jobsite solutions, outdoor and lifestyle products, and engineered fasteners to support the world's builders, tradespeople and DIYers. The Company's world class portfolio of trusted brands includes DEWALT®, CRAFTSMAN®, STANLEY®, BLACK+DECKER®, and Cub Cadet®. To learn more visit: or follow Stanley Black & Decker on Facebook, Instagram, LinkedIn and X. About Children's Miracle Network Hospitals Children's Miracle Network Hospitals was founded more than 40 years ago with the vision to Change Kids' Health, Change the Future. We've raised over $9 billion for 170 children's hospitals by empowering and engaging with local communities and businesses – and we're not done yet. All donations benefit local member hospitals to fund what's needed most, like critical life-saving treatments and healthcare services, innovative research, vital pediatric medical equipment, child life services that put kids' and families' minds at ease during difficult hospital stays, and financial assistance for families who could not otherwise afford these health services. Together, we can change kids' health. Together, we can change the future. To learn about Children's Miracle Network Hospitals and your local member children's hospital, visit About Ace Hardware Ace Hardware is the largest retailer-owned hardware cooperative in the world with over 5,800 locally owned and operated hardware stores in approximately 60 countries. Headquartered in Oak Brook, Ill., Ace and its subsidiaries operate an expansive network of distribution centers in the U.S. and have distribution capabilities in Ningbo, China; Cuautitlán Izcalli, Mexico. Ace also owns Ace Hardware Home Services, a collection of local service companies with experienced professionals dedicated to helping homeowners complete home maintenance tasks. Since 1924, Ace has become a part of local communities around the world and known as the place with the Helpful Hardware Folks. For more information, visit or *Rated among 25 leading competitive brands, based on online national survey of 261 DIY tool and residential outdoor power equipment owners ages 18+, conducted in 10/2024.
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Canadian defined benefit pension plans show increased funded levels in Q2: Aon
TORONTO, July 2, 2025 /CNW/ — Aon plc (NYSE: AON), a leading global professional services firm, announced today that the aggregate funded ratio for Canadian pension plans in the S&P/TSX Composite Index increased to 109 percent compared to 105.5 percent at the end of last quarter, according to the Aon Pension Risk Tracker. The Aon Pension Risk Tracker calculates the aggregate funded position on an accounting basis for companies in the S&P/TSX Composite Index with defined benefit plans. To access Aon's interactive tracker, which has been tracking this data since 2013, click here. Key findings for the quarter ending June 30, 2025 include: Pension assets gained 1.6 percent over the second quarter of 2025. The long-term Government of Canada bond yield increased 33 basis points (bps) relative to the previous quarter rate, and credit spreads narrowed by 9 bps. This combination resulted in an increase in discount rate of 24 basis points, to 4.67 percent. 'Pension plans regained the ground that they had lost in the first quarter of the year, but volatility and uncertainty are still the name of the game,' said Nathan LaPierre, partner for Wealth Solutions in Canada at Aon. 'Pension plan sponsors continue to evaluate how they may shield their plans from that uncertainty.' About AonAon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon's newsroom and sign up for news alerts here. Media ContactAlexandre Daudelin+1 514 967-9330
